COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing selected landmark randomized trials without systematic review methodology
PubMed 32921371 · doi:10.1016/j.iccl.2020.07.003
What was done
This narrative review summarizes key landmark clinical trials (including COURAGE, ORBITA, and ISCHEMIA) evaluating the role of percutaneous coronary intervention (PCI) versus medical therapy or placebo in stable coronary artery disease (CAD).
What was found
The abstract provides no quantitative data. It reports qualitatively that anginal relief remains the primary indication for PCI in stable CAD, with the first placebo-controlled trial demonstrating a surprisingly small effect size. Furthermore, PCI in stable CAD has not been shown to improve mortality or myocardial infarction rates compared to medical therapy, even among patients with significant ischemia.
Why it matters
It reinforces that medical therapy is the primary intervention for reducing clinical events in stable CAD, while PCI serves primarily for symptom relief.
Limits
As a narrative review, it lacks a systematic search methodology, meta-analytic pooling, and quantitative data in the abstract. It relies on syntheses of previously published trials rather than presenting new empirical data.
Cited by
- context Coronary stents do not prevent heart attacks.